January 24, 2023 09:00 AM ESTUpdated February 7, 09:34 AM

#JPM23: Fireside chat with Eisai's Ivan Cheung

Drew Armstrong

Executive Editor

Less than a week after Eisai and Biogen won accelerated approval from the FDA for their Alzheimer’s drug lecanemab, Executive Editor Drew Armstrong spoke one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#JPM23: Fireside chat with Eisai's Ivan Cheung

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

Executive Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#JPM23: Fireside chat with Eisai's Ivan Cheung